Current status of bacterial resistance to third-generation cephalosporins. 1992

J A García-Rodríguez, and J E García Sánchez, and J L Muñoz Bellido, and M I García García

A review of the evolution of bacterial resistance to third-generation cephalosporins is presented, focusing mainly on the prototypical member of this group-cefotaxime. Third-generation cephalosporins generally remain highly active against most Enterobacteriaceae, staphylococci, streptococci, Haemophilus, and Neisseriaceae. Only enterobacteria with a high frequency of mutant derepressed strains that hyperproduce chromosomally mediated beta-lactamase, Pseudomonas spp., and some glucose nonfermenter Gram-negative bacilli have demonstrated increased levels of resistance. The significance of derepressed strains and of the recently described extended-spectrum, plasmid-mediated beta-lactamases to the usefulness of the third-generation cephalosporins is discussed.

UI MeSH Term Description Entries
D002439 Cefotaxime Semisynthetic broad-spectrum cephalosporin. Benaxima,Biosint,Cefotaxim,Cefotaxime Sodium,Cefradil,Cephotaxim,Claforan,Fotexina,HR-756,Kendrick,Klaforan,Primafen,Ru-24756,Taporin,HR 756,HR756,Ru 24756,Ru24756,Sodium, Cefotaxime
D002511 Cephalosporins A group of broad-spectrum antibiotics first isolated from the Mediterranean fungus ACREMONIUM. They contain the beta-lactam moiety thia-azabicyclo-octenecarboxylic acid also called 7-aminocephalosporanic acid. Antibiotics, Cephalosporin,Cephalosporanic Acid,Cephalosporin,Cephalosporin Antibiotic,Cephalosporanic Acids,Acid, Cephalosporanic,Acids, Cephalosporanic,Antibiotic, Cephalosporin,Cephalosporin Antibiotics
D004352 Drug Resistance, Microbial The ability of microorganisms, especially bacteria, to resist or to become tolerant to chemotherapeutic agents, antimicrobial agents, or antibiotics. This resistance may be acquired through gene mutation or foreign DNA in transmissible plasmids (R FACTORS). Antibiotic Resistance,Antibiotic Resistance, Microbial,Antimicrobial Resistance, Drug,Antimicrobial Drug Resistance,Antimicrobial Drug Resistances,Antimicrobial Resistances, Drug,Drug Antimicrobial Resistance,Drug Antimicrobial Resistances,Drug Resistances, Microbial,Resistance, Antibiotic,Resistance, Drug Antimicrobial,Resistances, Drug Antimicrobial

Related Publications

J A García-Rodríguez, and J E García Sánchez, and J L Muñoz Bellido, and M I García García
January 1989, Infection,
J A García-Rodríguez, and J E García Sánchez, and J L Muñoz Bellido, and M I García García
April 2020, Mayo Clinic proceedings,
J A García-Rodríguez, and J E García Sánchez, and J L Muñoz Bellido, and M I García García
June 1993, The West Indian medical journal,
J A García-Rodríguez, and J E García Sánchez, and J L Muñoz Bellido, and M I García García
April 2020, Mayo Clinic proceedings,
J A García-Rodríguez, and J E García Sánchez, and J L Muñoz Bellido, and M I García García
August 1999, Journal of chemotherapy (Florence, Italy),
J A García-Rodríguez, and J E García Sánchez, and J L Muñoz Bellido, and M I García García
August 1987, European journal of clinical microbiology,
J A García-Rodríguez, and J E García Sánchez, and J L Muñoz Bellido, and M I García García
March 1983, The Journal of infectious diseases,
J A García-Rodríguez, and J E García Sánchez, and J L Muñoz Bellido, and M I García García
July 1995, The Medical clinics of North America,
J A García-Rodríguez, and J E García Sánchez, and J L Muñoz Bellido, and M I García García
December 1987, Indian pediatrics,
J A García-Rodríguez, and J E García Sánchez, and J L Muñoz Bellido, and M I García García
January 1982, The Medical clinics of North America,
Copied contents to your clipboard!